Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: progyny.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $30.00 | Hold → Buy | Canaccord Genuity |
| 1/20/2026 | $30.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 1/8/2026 | $34.00 | Hold → Buy | Truist |
| 12/9/2025 | $29.00 | Overweight | Barclays |
| 11/12/2025 | $30.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 7/8/2025 | $28.00 | Market Perform → Outperform | Leerink Partners |
| 12/2/2024 | $17.00 | Overweight → Neutral | Analyst |
| 11/13/2024 | $26.00 → $19.00 | Buy → Hold | Truist |
| 9/19/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | $37.00 → $24.00 | Buy → Hold | Canaccord Genuity |
144 - Progyny, Inc. (0001551306) (Subject)
8-K - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
10-Q - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
DEFA14A - Progyny, Inc. (0001551306) (Filer)
DEF 14A - Progyny, Inc. (0001551306) (Filer)
PRE 14A - Progyny, Inc. (0001551306) (Filer)
SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)
8-K - Progyny, Inc. (0001551306) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Canaccord Genuity upgraded Progyny from Hold to Buy and set a new price target of $30.00
Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00
Truist upgraded Progyny from Hold to Buy and set a new price target of $34.00
Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $29.00
KeyBanc Capital Markets upgraded Progyny from Sector Weight to Overweight and set a new price target of $30.00
Leerink Partners upgraded Progyny from Market Perform to Outperform and set a new price target of $28.00
Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00
Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously
JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform
Canaccord Genuity downgraded Progyny from Buy to Hold and set a new price target of $24.00 from $37.00 previously
Fastest customizable press release news feed in the world
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- A new survey from Progyny (NASDAQ:PGNY), a global leader in women's health and family building solutions, found that people navigating fertility, pregnancy, postpartum, and menopause care increasingly view personalized, human-led healthcare guidance as essential to managing stress and navigating a complex healthcare system. Among surveyed members, 71% said their healthcare journey added stress to their daily lives, with the top sources including the financial impact of healthcare and treatment, healthcare system complexity, and work/life balance challenges. Patients are not just managing healthcare decisions; they are also managing emotional stre
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances. Shares may be repurchased through open market repurchases, including through plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, depending on stock price, market conditions and other factors deemed relevant in the Company's sole discretion. The program may be suspended or discontinued at any time. There can be no assurances
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at http://investors.progyny.com. About Progyny Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leadin
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 ("the first quarter of 2026"), as compared to the three-month period ended March 31, 2025 ("the first quarter of 2025" or "the prior year period"). "We're pleased with the strong start to the ye
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model. As the rate of infertility continues to rise and national attention on fertility coverage accelerates, the company is helping to make family building and women's health a standard of care, not a privilege. "Progyny Select is a game-changer for small employers," said Pete Anevski, CEO of Progyny. "We'
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Over the past ten years, millions of individuals and families have gained access to life-changing benefits through Progyny, a global leader in women's health and family building solutions. Progyny today announces that throughout the year, it will honor the collective efforts of its members, employers, providers, and industry partners who have helped shape this decade of progress. The company has redefined what's possible in the benefits industry by combining clinical expertise, innovation, and a personalized approach to support members at every stage, from preconception through menopause. "Ten years ago, we set out to transform family building
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, will participate in a fireside chat on March 10, 2026, at 10:40 a.m. Eastern Time. At the Barclays Global Healthcare Conference, Pete Anevski, Chief Executive Officer, will participate in
Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using t
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
Live finance-specific insights
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 ("the first quarter of 2026"), as compared to the three-month period ended March 31, 2025 ("the first quarter of 2025" or "the prior year period"). "We're pleased with the strong start to the ye
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An
Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using t
Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2025 ("the third quarter of 2025"), as compared to the th
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2025 after the close of the market on Thursday, November 6, 2025. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcod
Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2025 ("the second quarter of 2025") as compared to the three-month period ended June 30, 2024 ("the second quarter of 2024" or "the prior year period"). "The strong second quarter results
Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the "revolver" or the "facility") which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expe
Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl
This live feed shows all institutional transactions in real time.
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
Live Leadership Updates
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025. Debra Morris currently serves as President of AccessHope, a company changing the way leading-edge cancer expertise is delivered. Previously she served as EVP and CFO of Apria Healthcare where she demonstrated her ability to navigate complex industry challenges, drive operational excellence, and deliver value to stakeholders. With her extensive board service and proven leadership in handling periods o
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care. Progyny's global benefits solution supports multinational employers and their employee populations in over 100 countries. Progyny's services allow employers the flexibility to offer fertility and family building benefits that co
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced two newly created roles with the appointment of Katie Higgins as Chief Commercial Officer and Steven Leist as Chief Technology Officer. "We are excited to expand our executive team and welcome Katie and Steven to Progyny. Their expertise will further advance our growth and momentum in the fertility, family building, and women's health benefits space," said Pete Anevski, Progyny's CEO. With over 25 years of healthcare experience, Katie Higgins will be overseeing the teams that drive revenue, business growth, and client succes
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of Janet Choi, M.D., as the company's Chief Medical Officer. Dr. Choi brings more than 20 years of experience in the field as a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. In her new role, she will lead clinical strategy working closely with the company's executive team and medical advisory board to ensure Progyny offers the highest quality and most effective family building and women's health benefits possible. "I am thrilled to offici